GE HealthCare's Flyrcado Sets New Benchmark in Cardiac PET Imaging
GE HealthCare GEHC recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emission Tomography (PET) imaging agent for myocardial perfusion imaging (MPI).
As cardiovascular disease continues to rise globally, GEHC emphasized Flyrcado's role in enabling more accurate diagnosis, treatment planning, and broader access to personalized cardiac care through advanced molecular imaging.
Flyrcado reflects GEHC's broader focus on advancing precision cardiac care through molecular imaging. It plays a key role in enabling earlier disease detection, personalizing treatment strategies, and monitoring therapy response or disease progression. The company highlighted Flyrcado at the 2025 SNMMI annual meeting, reinforcing its commitment to delivering advanced diagnostic tools that improve outcomes for the growing population at risk of cardiovascular disease.
GEHC's Flyrcado (flurpiridaz F 18) is a fluorine-18 PET MPI agent developed for patients with known or suspected coronary artery disease. Flyrcado has a longer half-life of approximately 110 minutes. This allows for centralized production and broad distribution. For the first time, it also enables the practical integration of exercise stress testing with cardiac PET imaging. Compatible with GEHC's Omni Legend PET/CT and other systems, the agent is designed to support detailed assessment of myocardial perfusion, ischemia, and infiltrative cardiomyopathies.
Recently launched in select U.S. markets, Flyrcado received CMS pass-through status effective April 1 and is supported by a specific HCPCS billing code. The agent is now covered by all seven Medicare Administrative Contractors and by more than 50% of commercial insurers under updated national and regional cardiac PET policies. Coverage has expanded beyond hospital outpatient settings, and GEHC has established a dedicated Flyrcado Support Center to assist providers with coding, benefits investigations, and claims submissions.
Shares of the company closed flat at $71.16 yesterday following the announcement. In the year-to-date period, GEHC shares have lost 9% against the industry's 4% growth. The S&P 500 increased 0.8% in the same time frame.
Flyrcado positions GEHC for long-term growth by expanding its presence in the high-value molecular imaging market, where demand for precision cardiac diagnostics is rising. With broad payer coverage, CMS reimbursement, and compatibility with existing PET/CT systems, Flyrcado can accelerate the shift from SPECT to PET imaging—unlocking recurring revenue from both radiopharmaceutical sales and imaging hardware. As adoption scales beyond hospitals in outpatient settings, Flyrcado strengthens GEHC's precision care portfolio and supports its strategy to drive margin expansion through innovation-led, high-utility diagnostics.
Meanwhile, GEHC currently has a market capitalization of $32.64 billion and carries a Zacks Rank #4 (Sell). In the last reported quarter, GEHC delivered an earnings surprise of 10.9%.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Image Source: Zacks Investment Research
Koninklijke Philips PHG has recently accelerated its cardiac imaging leadership through advanced AI integration in both CT and ultrasound modalities. In January 2025, the company launched the AI-enabled CT 5300, a 128-slice CT system equipped with AI-powered cardiac motion correction and reconstruction at AOCR 2025, enhancing image clarity, speeding workflows, and reducing radiation exposure in cardiac scans.
Complementing this, Philips' Spectral CT 7500 continues to deliver 'always-on' dual-layer spectral imaging, FDA-cleared for 4D respiratory-gated applications, offering clinicians the ability to assess coronary arteries and myocardial perfusion with superior diagnostic confidence during a single, swift scan.
Nano-X Imaging Ltd. NNOX through its AI imaging division Nanox.AI, received FDA 510(k) clearance for HealthCCSng V2.0 in August 2024, an AI-powered solution that automatically quantifies coronary artery calcium (CAC) from routine non-gated chest CT scans, adding a 'zero calcium' category and numerical scoring for more nuanced risk stratification.
At SCCT 2024, real-world studies were showcased, including evidence from Brigham & Women's Hospital demonstrating that HealthCCSng flagged incidental CAC in more than 50% of immune-mediated inflammatory disease patients highlighting its potential for early detection and preventive care across broad clinical settings.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report
Nano-X Imaging Ltd. (NNOX) : Free Stock Analysis Report
GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
37 minutes ago
- Business Insider
Cue Biopharma receives Pre-IND feedback from FDA for CUE-401
Cue Biopharma (CUE) announced it has received Pre-Investigational New Drug, or Pre-IND, feedback from the FDA. The FDA reviewed the first-in-human trial design, including the Company's plan for dose escalation, proposed populations and safety monitoring plan. On the basis of the FDA feedback, the Company, intends to file an IND pending completion of final IND enabling studies. CUE-401 is the Company's lead autoimmune asset, a first-in-class bispecific fusion protein/molecule designed to induce and expand regulatory T cells in vivo through the co-activity of transforming growth factor beta and a modified variant of interleukin.
Business Insider
an hour ago
- Business Insider
Stock Market News Review: SPY, QQQ Surge on Israel-Iran Ceasefire, EU Tariff Threat
Israel and Iran have officially agreed to a ceasefire, providing a boost to both the S&P 500 (SPX) and the Nasdaq 100 (NDX). Both countries have begun preparations to open up their respective airspaces as the threat of missiles disappears. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter 'Both Israel and Iran wanted to stop the War, equally! It was my great honor to Destroy All Nuclear facilities & capability, and then, STOP THE WAR!' said President Trump on Truth Social. While Trump was able to broker a ceasefire, his efforts to pressure the Fed to lower interest rates remain unsuccessful. On Tuesday, Fed Chair Jerome Powell said that the central bank is in a good position to maintain its 'wait-and-see' approach before adjusting interest rates. The Fed has declined to lower rates given the risk of a tariff-driven inflation revival during the second half of the year. Meanwhile, consumer sentiment took a step back in June, as the Consumer Confidence Index registered a reading of 93.0 compared to the expectation for 99.8 and falling from 98.4 in May. Furthermore, current and future sentiment toward business and labor market conditions fell as consumers remain worried about the effects of tariffs. On the bright side, the 12-month average inflation expectation dropped to 6.0% from 6.4% in May and 7.0% in April. On the trade front, the European Union is prepared to deliver retaliatory tariff threats to the U.S. in order to secure a better trade deal, reported the Financial Times. Bjoern Seibert, Chief of Staff to the European Commission President, has initiated the process of collecting support to tariff approximately $110 billion of U.S. goods. In addition, the EU may increase tariffs on U.S. technology companies while increasing non-tariff measures on other American companies. 'We're ready to use a variety of options if there is no deal. We can and we will defend our interests,' said German Chancellor Friedrich Merz. Finally, a White House official has confirmed that President Trump will meet with Ukrainian President Volodymyr Zelensky during the NATO Summit in The Hague. Zelensky was unable to meet with Trump during the G7 Summit as a result of his early departure in order to address the Israel-Iran war situation. The S&P 500 closed with a 1.11% gain while the Nasdaq 100
Business Insider
an hour ago
- Business Insider
Capricor Therapeutics price target lowered to $29 from $40 at JonesResearch
JonesResearch lowered the firm's price target on Capricor Therapeutics (CAPR) to $29 from $40 and keeps a Buy rating on the shares. The company confirmed the FDA will not hold a panel meeting for deramiocel in Duchenne muscular dystrophy, the analyst tells investors in a research note. The firm says that while there are cases where canceled panel meetings led to FDA approval, it is inclined to believe the decision signals a complete response letter or FDA action date extension. Center for Biologics Evaluation and Research director Dr. Vinay Prasad has been a vocal advocate for increased regulatory stringency, even in DMD, contends JonesResearch. If the FDA issues a CRL, approval would be pushed to mid 2026, the firm adds. It reduced the probability of approval to 45% from 65%, driving the target cut. Confident Investing Starts Here:
